These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1150 related articles for article (PubMed ID: 2306755)

  • 1. Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia.
    Rajaram N; Tatake RJ; Advani SH; Naik SL; Gangal SG
    Cancer Immunol Immunother; 1990; 31(1):44-8. PubMed ID: 2306755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells.
    Roger R; Issaad C; Pallardy M; Léglise MC; Turhan AG; Bertoglio J; Bréard J
    Blood; 1996 Feb; 87(3):1113-22. PubMed ID: 8562937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity.
    Verfaillie C; Miller W; Kay N; McGlave P
    Blood; 1989 Aug; 74(2):793-7. PubMed ID: 2473805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia.
    Verfaillie C; Kay N; Miller W; McGlave P
    Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous lymphokine activated killer cell activity and cytogenetic response in chronic myelogenous leukaemia treated with alpha-interferon.
    Meseri A; Delwail V; Brizard A; Lecron JC; Pelletier D; Guilhot F; Tanzer J; Goube de Laforest P
    Br J Haematol; 1993 Feb; 83(2):218-22. PubMed ID: 8457470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes.
    Komatsu F; Kihara K
    Clin Immunol Immunopathol; 1995 Oct; 77(1):75-81. PubMed ID: 7554487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer and lymphokine activated killer cell functions in Hodgkin's disease.
    Rajaram N; Tatake RJ; Advani SH; Gangal SG
    Br J Cancer; 1990 Aug; 62(2):205-8. PubMed ID: 2386735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.
    Silla LM; Pincus SM; Locker JD; Glover J; Elder EM; Donnenberg AD; Nardi NB; Bryant J; Ball ED; Whiteside TL
    Br J Haematol; 1996 May; 93(2):375-85. PubMed ID: 8639431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphokine-activated killer cell functions in patients with leukemic B-lymphoproliferative diseases.
    van der Harst D; Brand A; van Luxemburg-Heys SA; Kooy-Winkelaar EM; van Rood JJ
    Blood; 1989 Nov; 74(7):2464-70. PubMed ID: 2804374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytolytic activity by lymphokines (LAK activity) in chronic myeloid leukemia].
    Cervantes F; Miller JS; McGlave PB
    Med Clin (Barc); 1995 Jun; 105(2):50-3. PubMed ID: 7603094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of alpha-interferon on MHC unrestricted cytotoxicity in chronic myelogenous leukemia.
    Meseri-Delwail A; Delwail V; Brizard A; Goube de Laforest P; Guilhot F; Lecron JC
    Biotechnol Ther; 1994; 5(1-2):47-57. PubMed ID: 7703832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
    Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
    Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PGE2, but not TGF beta 2, in rabbit blastocoelic fluid regulates the cytotoxic activities of NK and LAK cells.
    Bergeron D; Ouellette MJ; Lambert RD
    J Reprod Immunol; 1997 Jul; 33(3):203-19. PubMed ID: 9255724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The heterogeneity of target recognition by lymphokine-activated killer precursor cells.
    Ibayashi Y; Gray JD; Golub SH; Daibo M; Yamaki T; Kawahara T; Kubota T; Hashi K
    Jpn J Cancer Res; 1990 Sep; 81(9):927-35. PubMed ID: 2121694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha.
    Pawelec G; Da Silva P; Max H; Kalbacher H; Schmidt H; Bruserud O; Zügel U; Baier W; Rehbein A; Pohla H
    Leuk Lymphoma; 1995 Aug; 18(5-6):471-8. PubMed ID: 8528055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.
    Subauste CS; Dawson L; Remington JS
    J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
    Pierson BA; Miller JS
    Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission.
    Dabholkar M; Tatake R; Amin K; Advani S; Gangal S
    Oncology; 1989; 46(2):123-7. PubMed ID: 2785254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.